Epigenetic targets and drug discovery: Part 1: Histone methylation. Read more about Epigenetic targets and drug discovery: Part 1: Histone methylation.
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Read more about Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.
Copper is required for oncogenic BRAF signalling and tumorigenesis. Read more about Copper is required for oncogenic BRAF signalling and tumorigenesis.
Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? Read more about Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Modulation of the chromatin phosphoproteome by the Haspin protein kinase. Read more about Modulation of the chromatin phosphoproteome by the Haspin protein kinase.
Targeting bromodomains: epigenetic readers of lysine acetylation. Read more about Targeting bromodomains: epigenetic readers of lysine acetylation.
Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors. Read more about Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors.
Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single stranded m6A RNA demethylation. Read more about Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single stranded m6A RNA demethylation.
Human UTY(KDM6C) is a Male-Specific N{epsilon}-Methyl Lysyl-Demethylase. Read more about Human UTY(KDM6C) is a Male-Specific N{epsilon}-Methyl Lysyl-Demethylase.
A Chromatin-Dependent Role of the Fragile X Mental Retardation Protein FMRP in the DNA Damage Response. Read more about A Chromatin-Dependent Role of the Fragile X Mental Retardation Protein FMRP in the DNA Damage Response.
